add items to your
binder to email or
print all at once
Items In Binder
Site Lawyers
 

Industry Overview

Healthcare

Cravath represents some of the largest and most highly regarded companies in the healthcare industry, providing counsel on a variety of corporate and litigation matters. We have played a leading role in critical and complex transactions that have defined the healthcare industry, creating long‑standing client relationships that have further developed our ability to handle matters in this sector.

We have been involved in some of the largest and most significant healthcare merger and acquisition transactions, representing: Schering in its €16.3 billion acquisition by Bayer and the competing offer from Merck; Life Technologies in its $15.8 billion sale to Thermo Fisher Scientific; Mylan in numerous transactions including its pending $50 billion combination with Upjohn, a division of Pfizer, its $9.9 billion acquisition of Meda; its $5.6 billion inversion acquisition of certain businesses of Abbott Laboratories; and its €4.9 billion purchase of the generic‑drug operations of Merck; Novartis in its $29.8 billion spin-off of Alcon; Linde in its $4.6 billion acquisition of Lincare Holdings; and AmerisourceBergen in its strategic, long‑term relationship with Walgreens and Alliance Boots. Cravath represented Bristol‑Myers Squibb and Mead Johnson in its IPO and Bristol‑Myers Squibb in the subsequent split‑off of Mead Johnson. We also regularly represent Johnson & Johnson in a variety of acquisitions and divestitures, including its $30 billion acquisition of Actelion, its $19.7 billion acquisition of Synthes and its $16.6 billion acquisition of Pfizer’s consumer products businesses.

Cravath also handles trial, appellate, and criminal/regulatory matters for pharmaceutical, biotechnology, healthcare services and medical device companies, including complex intellectual property and antitrust litigation, class action, shareholder derivative and securities suits, breach of contract disputes and licensing disputes and arbitrations, and regulatory clearance and antitrust advice relating to mergers and acquisitions. Cravath obtained a jury verdict in favor of Novartis Pharmaceuticals Corporation in its patent infringement suit against Teva Pharmaceuticals concerning Novartis’s drug, Famvir®; obtained a $750 million settlement for stent manufacturer Medinol Ltd. after a seven‑week trial against Boston Scientific Corporation for breach of contract; and secured a damage award of over $442 million for Bristol‑Myers Squibb and Sanofi‑Aventis in their patent infringement litigation against Apotex regarding Plavix®, as well as the dismissal of four Plavix‑related antitrust actions against Bristol‑Myers Squibb. Cravath has successfully represented Johnson & Johnson in class action shareholder litigation in connection with Johnson & Johnson’s acquisitions of Mentor Corporation and Omrix Biopharmaceuticals, Inc. and the independent directors of Par Pharmaceuticals in shareholder litigation concerning its $1.9 billion acquisition by TPG Capital. Cravath is currently representing Merck & Co. and many of its current and former officers and directors in federal securities actions arising out of alleged misrepresentations and omissions relating to Merck’s sale of VIOXX®. Cravath also represented Merck in related shareholder derivative litigation and an ERISA class action. Cravath is presently representing Mylan in three appeals regarding patent infringement before the Federal Circuit concerning drugs used to treat pulmonary disease, multiple sclerosis and acquired immune deficiency syndrome, and successfully represented Mylan as trial counsel in a separate patent infringement action.

Cravath’s other clients in this industry have included Alpharma, Aptuit, Ariad Pharmaceuticals, Bayer AG, Berlex Laboratories, Biogen, Chemed, Drug Royalty, GlaxoSmithKline, InterMune, King Pharmaceuticals, Kos Pharmaceuticals, Millipore, Noven Pharmaceuticals, OrbusNeich, Schering AG, the Special Committee of the Board of Directors of Assisted Living Concepts and Universal Health Services.

Experience from Cravath’s long‑standing relationships with some of the leading companies in this industry well qualifies it to handle important transactions and disputes in this area.